Table 4.
Serious adverse events
| Serious adverse events | Cohort 1 + 2, N = 6 (%) | Cohort 3 + 4, N = 15 (%) |
|---|---|---|
| Intraductal proliferative breast lesion | 1 (16.7) | 0 (0) |
| Macular hole | 0 (0) | 1 (6.7) |
| Osteoarthritis | 1 (16.7) | 0 (0) |
| Pneumonia | 1 (16.7) | 0 (0) |
| Pneumothorax | 0 (0) | 1 (6.7) |
| Urinary tract infection | 0 (0) | 1 (6.7) |